Patents by Inventor Shanmuganathan Chandrakasan

Shanmuganathan Chandrakasan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOSITIONS AND METHODS FOR PROMOTING HEMATOPOIETIC CELL CYTOTOXICITY
    Publication number: 20220378827
    Abstract: Provided herein are compositions and methods for promoting hematopoietic cell cytotoxicity.
    Type: Application
    Filed: April 12, 2020
    Publication date: December 1, 2022
    Applicants: EMORY UNIVERSITY, CHILDREN'S HEALTHCARE OF ATLANTA, INC., EXPRESSION THERAPEUTICS LLC
    Inventors: Harold Trent Spencer, Christopher Doering, Shanmuganathan Chandrakasan, Lauren Fleischer, Jaquelyn Zoine, Gianna Branella, Harrison C. Brown
  • COMPOSITIONS AND METHODS FOR TREATMENT OF HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS
    Publication number: 20210393687
    Abstract: Provided herein are nucleic acids, vectors, and cells containing an expression-optimized codon that encodes a Munc13-4 polypeptide or a STXBP2 polypeptide. Also provided are methods of making and using the nucleic acids, vectors, and cells. Also provided herein are methods of treating of Hemophagocytic Lymphohistiocytosis (HLH) in a subject.
    Type: Application
    Filed: October 1, 2019
    Publication date: December 23, 2021
    Applicants: EMORY UNIVERSITY, CHILDREN'S HEALTHCARE OF ATLANTA, INC.
    Inventors: Harold Trent Spencer, Christopher Doering, Shanmuganathan Chandrakasan, Sarah Takushi
  • Use of KIT inhibitors to condition subjects for a hematopoietic stem cell (HSC) transplantation
    Patent number: 10889646
    Abstract: Provided herein are compositions and methods related to conditioning a subject for a hematopoietic stem cell (HSC) transplantation using an inhibitor of a stem cell growth factor receptor (KIT). The compositions and methods described herein are particularly useful for a subject who is in need of a HSC transplantation and who is hypersensitive to at least one DNA damaging agent, e.g., a subject with fanconi anemia. Compositions and methods related to conditioning a fanconi anemia subject for HSC transplantation using an inhibitor of KIT are also provided herein.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: January 12, 2021
    Assignee: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Punam Malik, Shanmuganathan Chandrakasan
  • USE OF KIT INHIBITORS TO CONDITION SUBJECTS FOR A HEMATOPOIETIC STEM CELL (HSC) TRANSPLANTATION
    Publication number: 20180127497
    Abstract: Provided herein are compositions and methods related to conditioning a subject for a hematopoietic stem cell (HSC) transplantation using an inhibitor of a stem cell growth factor receptor (KIT). The compositions and methods described herein are particularly useful for a subject who is in need of a HSC transplantation and who is hypersensitive to at least one DNA damaging agent, e.g., a subject with fanconi anemia. Compositions and methods related to conditioning a fanconi anemia subject for HSC transplantation using an inhibitor of KIT are also provided herein.
    Type: Application
    Filed: March 25, 2016
    Publication date: May 10, 2018
    Applicant: Children's Hospital Medical Center
    Inventors: Punam Malik, Shanmuganathan Chandrakasan